How we do more with partners

Under the clinical leadership of TGen’s Dr. Daniel Von Hoff, and with key Arizona partners, we are at the forefront of precision medicine clinical trials for rare and common cancers. These trials provide options for patients here in Arizona, while working to gain approval by the FDA, which opens doors nationally.

TGen successfully led a Phase I clinical trial at HonorHealth for a rare form of skin cancer, which was followed by a Mayo Clinic Arizona-led phase II clinical trial. These studies resulted in the first drug to receive FDA approval to treat inoperable basal cell carcinoma. Both studies were published in the prestigious New England Journal of Medicine.

Von Hoff’s work in pancreatic cancer and my work in melanoma are funded by Stand Up to Cancer (SU2C), which includes partners in Arizona (Mayo Clinic Arizona and HonorHealth) as well as national and international partners including the Salk Institute, Yale University and Cambridge University.

Von Hoff’s SU2C Dream Team has again led to FDA approval of new treatments for pancreatic cancer patients in Arizona, thus opening opportunity for these treatments to be used nationwide.

Through our recent affiliation with City of Hope in Duarte, Calif., we have created a plan outlining a shared vision that aligns TGen’s translational science with City of Hope’s clinical expertise to pursue significant improvements in patient care — everything from wearable devices to new methods of early disease detection.

A model of productive research between TGen and our university partnerships is our expanding efforts with Northern Arizona University in the study of deadly infectious disease, combating international bioterrorism, and investigating contagious outbreaks worldwide. We are developing rapid, low-cost and highly accurate geneticbased tests for Valley Fever, Klebsiella, Lyme disease, and antibiotic-resistant strains of Staph infections, such as MRSA.

Nationally, working with clinical leadership from the University of California San Francisco, and funded by The Ben & Catherine Ivy Foundation of Scottsdale, TGen is partnering with clinical academic partners across the nation to develop new therapeutics against glioblastoma, the most common and aggressive type of primary brain tumor.

Locally, a new partnership with Banner Health and TGen’s Neurogenomics Division is expanding research into concussions and brain injuries, building on our ongoing research with Riddell, the ASU football team, and Barrow Neurological Institute.

Impact translates economically

Since its inception in 2002, TGen has brought into Arizona more than $1 billion